NYSE:ABTMedical Equipment
Abbott (ABT) Lands Exclusive Rights To FDA Approved SimpleScreen In The U.S.
FDA has approved Freenome's SimpleScreen blood-based colorectal cancer test for average-risk adults.
Abbott Laboratories, NYSE:ABT, holds exclusive rights to commercialize SimpleScreen in the U.S.
This agreement expands Abbott's colorectal cancer screening portfolio and strengthens its role in blood-based diagnostics.
Abbott Laboratories, NYSE:ABT, is moving into a higher profile position in colorectal cancer screening through this new U.S. commercialization partnership for SimpleScreen...